Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6293912 | 0.88 | NR3C1 (0.50) | POLBPDE4BLMNAADORA1KMT2A | |
| SCHEMBL6290687 | 0.85 | LMNA (0.56) | POLBPDE4BLMNAKMT2ANR3C1 | |
| SCHEMBL6289510 | 0.84 | PDE4B (0.48) | POLBPDE4BLMNAADORA1KMT2A | |
| SCHEMBL6290650 | 0.81 | LMNA (0.49) | POLBPDE4BLMNAADORA1KMT2A | |
| SCHEMBL6290788 | 0.81 | MMP1 (0.54) | POLBLMNAADORA1KMT2ANR3C1 | |
| SCHEMBL6290579 | 0.76 | MMP1 (0.53) | POLBPDE4BLMNANR3C1PKM | |
| SCHEMBL6293248 | 0.76 | PDE4B (0.40) | PDE4BLMNAADORA1KMT2APKM | |
| SCHEMBL7008676 | 0.75 | LMNA (0.66) | POLBLMNAKMT2ANR3C1PKM | |
| SCHEMBL6290603 | 0.75 | PDE4B (0.47) | POLBPDE4BLMNAADORA1PKM | |
| SCHEMBL6289454 | 0.74 | CA2 (0.43) | PDE4BLMNAKMT2APKMMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6946473-B2 | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors | WYETH HOLDINGS CORPORATION (US) | 2005-09-20 | — | — | US | disclosed |
| US-20030208066-A1 | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors | AMERICAN CYANAMID COMPANY | 2003-11-06 | — | — | US | disclosed |
| EP-1279674-A2 | Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors | American Cyanamid Company (US) | 2003-01-29 | — | — | EP | disclosed |
| EP-1157024-B1 | ACETYLENIC ORTHO-SULFONAMIDO AND PHOSPHINIC ACID AMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS TACE INHIBITORS | AMERICAN CYANAMID CO (US) | 2002-11-06 | — | — | EP | disclosed |
| EP-1157024-A1 | ACETYLENIC ORTHO-SULFONAMIDO AND PHOSPHINIC ACID AMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS TACE INHIBITORS | American Cyanamid Company (US) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000044749-A1 | ACETYLENIC ORTHO-SULFONAMIDO AND PHOSPHINIC ACID AMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030208066-A1 | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors | SI, TNF, PTDSS1 | POLB 971/4885PDE4B 3874/4885LMNA 2997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.